We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has earned a consensus rating of “Buy” from the nine ...

Bleakley Financial Group LLC cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 9.4% in the ...

Protagonist Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...

Analyst Devarakonda holds a conference call with CEO Patel to discuss ahead of key readouts in 1H25 in PV and PsO on February 13 at 1 pm.

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics (PTGX – Research ...

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice ...

Protagonist Therapeutics, Inc. (PTGX) stock price is 38.36 and Protagonist Therapeutics, Inc. (PTGX) 10-day simple moving average is 37.22. Protagonist Therapeutics, Inc. (PTGX) stock price is 38. ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

On Thursday, Clear Street initiated coverage on Protagonist Therapeutics (NASDAQ: NASDAQ:PTGX), currently valued at $2.4 billion, with a Buy rating and a price target of $63.00.